Skip to content

Sign in Start free

Create your free account

Loading…

We care for the people who care.

No ads. No selling of your data. No third-party trackers.

Apps

Prognia
Ward
Suture
Osler

Library

Guidelines
Medicines
Articles
Calculators
Explore decks
Institutions
Pharmaceutical companies
Blog

Prognia

About
Pricing
Contact

Support us

Founders Wall

For organisations

Hospitals
Universities and medical schools
Pharmaceutical companies

© 2026 Prognia · Amsterdam, the NetherlandsPrivacy TermsExchangeRate-API

Loading…

Articles
Oncology

Liver Cancer

EMERALD-3: Is STRIDE-Based TACE Combination Therapy a Breakthrough for Embolization-Eligible Unresectable HCC?

27 October 2026Original research1 min read

By Masatoshi Kudo.

Read the original

On this page

Abstract
Keywords
Authors
Source

Abstract

Masatoshi Kudo; EMERALD-3: Is STRIDE-Based TACE Combination Therapy a Breakthrough for Embolization-Eligible Unresectable HCC?, Liver Cancer, , admag018, h

Keywords

Hepatocellular Carcinoma Treatment and Prognosis
Open access

Authors

Masatoshi Kudo

Source

Published in Liver Cancer. The abstract is shown as published and remains the work of its authors; read the full article at the source.

doi.org/10.1159/lic/admag018

Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.

At a glance

Journal: Liver Cancer
Type: Original research
Published: 27 October 2026
Specialty: Oncology
Read time: 1 min

More in oncology

Hepatocellular carcinoma surveillance in MASLD: from cirrhosis-based screening to personalized risk stratificationAnnals of Hepatology · 2026Added todayNew
Pan-cancer bioinformatics analysis of vascular endothelial growth factor A (VEGFA) across genomic, transcriptomic, clinical, immune, and pharmacogenomic datasets

Read around a topic while you study.

Ward brings these articles into the same app as your cards and questions. One free account for Ward, Suture, Osler and Prognia.

Authors

1

DOI

10.1159/lic/admag018

In Silico Research in Biomedicine · 2026

Added todayNew

SystematicIn Silico Research in Biomedicine · 2026Added todayNew

Integrated transcriptomic analysis and computational evaluation of flavonoid-based PTGS2 inhibitors for potential therapeutic application in hepatocellular carcinomaIn Silico Research in Biomedicine · 2026Added todayNew

Tumor-area mitosis proportion as an image-derived mitotic phenotype in lung squamous cell carcinoma: Patient-level prognostic and multi-omics evaluationJournal of Pathology Informatics · 2026Added todayNew

HPV prevalence and genotype distribution in rare cervical adenocarcinoma subtypes: A 10-year retrospective cohort study from BrazilPreventive Medicine Reports · 2026Added todayNew

Survival Outcomes in Metastatic Colorectal Cancer Patients with BRAF Mutations Undergoing Targeted Chemotherapy: A Reconstructed Individual Patient Data Meta-Analysis of Randomized Controlled TrialsJournal of gastrointestinal cancer · 2026Added todayNew

Temporal trends in radiation-induced optic neuropathy: a meta-analysisClinical and Translational Radiation Oncology · 2026Added todayNew

Radiation-induced contrast enhancement in patients withClinical and Translational Radiation Oncology · 2026Added todayNew

A Novel Hybrid Endovascular Technique for Tympanojugular Paraganglioma: Flow Diversion Followed by Direct Transauricular Squid EmbolizationNeurointervention · 2026Added todayNew

A CTCF-LDHB axis converts nuclear lactate availability into an H3K18 acylation switch that directs alternative splicing in hypoxic breast cancerbioRxiv · 2026Added todayNew

Vault Packaging Dynamics: Cargo Loading Stabilizes MVP Conformation for High-Payload Cytokine Delivery in Cancer TherapybioRxiv · 2026Added todayNew